Vivani Medical VANI Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Net Income Loss by Business | |||
| Biopharm Division | -$24.15M-13.6% | -$21.26M-4.9% | |
| Neurostimulation Division | -$2.51M-12.3% | -$2.23M+58.6% | |
| Other Nonoperating Income Expense by Business | |||
| Biopharm Division | $823K-38.9% | $1.35M-5.5% | |
| Neurostimulation Division | $126K+181% | -$156K-38.1% | |
| Operating Expenses by Business | |||
| Biopharm Division | $25M— | —— | |
| Neurostimulation Division | $2.6M— | —— | |
| Total Assets by Business | |||
| Biopharm Division | $126.4M— | —— | |
| Other General And Administrative Expense by Business | |||
| Biopharm Division | $784K-3.6% | $813K-14.0% | |
| Neurostimulation Division | $325K— | —— | |
| Operating Lease Expense by Business | |||
| Biopharm Division | $4.21M+5.4% | $4M+0.2% | |
| Neurostimulation Division | $319K— | —— | |
| Labor And Related Expense by Business | |||
| Biopharm Division | $10.28M+2.2% | $10.05M+3.4% | |
| Neurostimulation Division | $1.14M-35.0% | $1.75M-46.9% | |
| Depreciation And Amortization by Business | |||
| Biopharm Division | $410K+8.5% | $378K+23.1% | |
| Neurostimulation Division | $13K-56.7% | $30K-31.8% | |
| Professional Services And Insurance Expense by Business | |||
| Biopharm Division | $4.91M+6.8% | $4.6M+11.0% | |
| Neurostimulation Division | $836K— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vivani Medical break its business down?
- Vivani Medical (VANI) reports net income loss by business across 3 parts — Biopharm Division, Neuromodulation Division and Neurostimulation Division. Each is extracted from the segment footnotes and tracked over time.
- Where does Vivani Medical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vivani Medical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.